Related Experiment Video

Updated: May 10, 2026

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Ustekinumab for psoriatic arthritis: close to the PSUMMIT?

Richard B Warren1, Hector Chinoy

  • 1Dermatology Centre, Salford Royal National Health Service Foundation Trust, University of Manchester, Manchester M6 8HD, UK. richard.warren@manchester.ac.uk

Lancet (London, England)
|June 18, 2013
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis04:47

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...